Corbus Pharmaceuticals’ Investigational Scleroderma Drug Takes Novel Approach To Treating Inflammation
Yuval Cohen (PhD), Chief Executive of Corbus Pharmaceuticals A new proposed treatment for scleroderma will soon be in Phase 2 clinical trials. Corbus Pharmaceuticals, based in Norwood, Massachusetts, recently received clearance from the FDA for their investigational new drug (IND),…